Axcella Health, Inc.
$71 Million - Initial Public OfferingJoint Bookrunner
Trevi Therapeutics, Inc.
$55 Million - Initial Public OfferingJoint Bookrunner
Zai Lab Limited
$200 Million - Follow-OnJoint Bookrunner
Medical Devices-Cardiology/U.S. TAVR Survey: 1Q19 Again Light vs. Street, Points to In-Line Sales, at Best
Biotechnology/Takeaways from the SVB Leerink GHC Immuno-Oncology Panel
Biotechnology/MEDACorp Hemophilia Survey Highlights Unmet Need For Next-Gen Disruptor Agents